Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
World game at war: why some European nations have threatened a World Cup boycott 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
LOS ANGELES, April 24, 2018 -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has entered into a $250,000 initial sales agreement with Vage Nigeria Ltd. (“Vage”), a brand support company specializing in product sourcing.
According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks.
Dr. Christopher Otiko, President of ViaDerma, stated “We are very pleased to be working together with Vage and their CEO, Kunle Craig to provide Vitastem to the people of Nigeria. This is only the first of many orders we expect to receive from Vage going forward.”
Kunle Craig, CEO of Vage Nigeria Ltd., commented, “Vitastem is a wonderful ointment that has exceeded all expectations during our testing. The feedback received and the results we have seen have so far been 100% positive. Infections have cleared up in just 3 days, and leg burns have seen significant improvement within 24 hours of application. I’ve witnessed firsthand the positive results brought upon by Vitastem in wound and skin treatment, and I have become a firm believer in this product. From what I have observed, Vitastem is a revolutionary medication.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: [email protected]
Phone: 310-374-6111
